Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29930977 | 1.00 | SGMS2 (0.54) | SGMS2HPGDLMNAGAAPTGER1 | |
| SCHEMBL978857 | 0.88 | HTT (0.64) | SGMS2LMNAGAAPTGER1BRD4 | |
| SCHEMBL25720776 | 0.85 | MAPT (0.63) | SGMS2HPGDLMNAGAAPTGER1 | |
| SCHEMBL1305662 | 0.85 | HPGD (0.57) | SGMS2HPGDLMNAGAAPTGER1 | |
| SCHEMBL1097551 | 0.85 | SGMS2 (0.54) | SGMS2HPGDLMNAGAAPTGER1 | |
| SCHEMBL23231164 | 0.85 | SGMS2 (0.61) | SGMS2LMNAGAAPTGER1BRD4 | |
| SCHEMBL19511860 | 0.85 | PTGER1 (0.49) | SGMS2GAAPTGER1BRD4MAPT | |
| SCHEMBL7050350 | 0.84 | PTGER1 (0.61) | SGMS2GAAPTGER1MAPTL3MBTL1 | |
| SCHEMBL34466882 | 0.84 | L3MBTL1 (0.53) | SGMS2HPGDLMNAGAAPTGER1 | |
| SCHEMBL23611725 | 0.84 | NPC1 (0.60) | SGMS2HPGDLMNAPTGER1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4085056-A1 | POLYCYCLIC AMIDES AS UBE2K MODULATORS FOR TREATING CANCER | Berg LLC (US) | 2022-11-09 | — | — | EP | disclosed |
| CN-115210229-A | Polycyclic amides as UBE2K modulators for the treatment of cancer | 博格有限责任公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-115175905-A | ZESTE enhancer homolog 2 inhibitors and uses thereof | 四川海思科制药有限公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2022-01-06 | — | — | US | disclosed |
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2022-01-06 | — | — | US | disclosed |
| US-11091447-B2 | UBE2K modulators and methods for their use | BERG LLC (US) | 2021-08-17 | — | — | US | disclosed |
| US-11091447-B2 | UBE2K modulators and methods for their use | BERG LLC (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210214320-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2021-07-15 | — | — | US | disclosed |
| US-20210214320-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2021-07-15 | — | — | US | disclosed |
| WO-2021138540-A1 | POLYCYCLIC AMIDES AS UBE2K MODULATORS FOR TREATING CANCER | BERG LLC (US) | 2021-07-08 | — | — | WO | disclosed |
| WO-2021138540-A1 | POLYCYCLIC AMIDES AS UBE2K MODULATORS FOR TREATING CANCER | BERG LLC (US) | 2021-07-08 | — | — | WO | disclosed |
| CN-104045552-A | Medicinal compound as neuroprotective agent | SHANGHAI SIMCERE PHARMACEUTICAL RES CO LTD | 2014-09-17 | — | — | CN | disclosed |
| US-20060247303-A1 | 7H-dibenzo[b,g][1,5]dioxocin-5-one derivatives and use thereof | BAYER HEALTHCARE AG (DE) | 2006-11-02 | — | — | US | disclosed |
| EP-1560630-A2 | 7H-DIBENZO[B,G][1,5]DIOXOCIN-5-ONE DERIVATIVES AND USE THEREOF | Bayer HealthCare AG (DE) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004039453-A2 | 7H-DIBENZO[B,G][1,5]DIOXOCIN-5-ONE DERIVATIVES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091447-B2 | UBE2K modulators and methods for their use | UBE2N, UBE2B, UBE2E1 | SGMS2 3608/4885HPGD 1216/4885LMNA 3530/4885 |
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | UBE2N, UBE2B, UBE2E1 | SGMS2 3608/4885HPGD 1216/4885LMNA 3530/4885 |
| US-20210214320-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | UBE2N, UBE2B, UBE2E1 | SGMS2 3608/4885HPGD 1216/4885LMNA 3530/4885 |
| US-20060247303-A1 | 7H-dibenzo[b,g][1,5]dioxocin-5-one derivatives and use thereof | CETP, APOB, MTTP | SGMS2 327/4885HPGD 2398/4885LMNA 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.